『ALL Hub』のカバーアート

ALL Hub

ALL Hub

著者： Scientific Education Support
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in ALL. Our aim is to enhance knowledge in ALL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
エピソード
  • How should patients with ALL be selected for blinatumomab treatment?

    How should patients with ALL be selected for blinatumomab treatment?
    2026/10/15
    The ALL Hub was pleased to speak with Sabina Chiaretti, Sapienza University, Rome, IT. We asked, What are the key considerations when determining the number and duration of blinatumomab treatment cycles? In this interview, Chiaretti discusses the key considerations when determining the number and duration of blinatumomab treatment cycles in B-ALL. She highlights factors that may inform treatment duration, including Philadelphia chromosome status, MRD response and genomic features. She also discusses clinical evidence supporting different treatment schedules across B-ALL treatment settings and the ongoing investigations into the optimal number and duration of blinatumomab cycles. Intended for healthcare professionals. This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    4 分
  • What is the potential impact of integrating reduced-chemo and chemo-free approaches into ALL treatment strategies? 

    What is the potential impact of integrating reduced-chemo and chemo-free approaches into ALL treatment strategies? 
    2026/09/29

    The ALL Hub was pleased to speak with Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, What is the potential impact of integrating reduced-chemotherapy and chemotherapy-free approaches into acute lymphoblastic leukemia (ALL) treatment strategies?


    In this interview, Jabbour discusses the growing evidence supporting chemotherapy-reduced and chemotherapy-free treatment approaches in ALL. He highlights how advances in targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors, and CAR T-cell therapy, together with measurable residual disease-guided treatment strategies, are transforming the management of ALL. Drawing on recent clinical studies, he explores the potential to reduce chemotherapy intensity, minimize the need for allogeneic stem cell transplantation, and improve long-term outcomes across different ALL subtypes and patient populations.


    This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    5 分
  • Obe-cel for relapsed/​refractory B-ALL: The FELIX study

    Obe-cel for relapsed/​refractory B-ALL: The FELIX study
    2026/08/11

    During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.


    This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    37 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません